Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine (CAREER)
Changes of Cognitive Function in Patients With Mild to Moderate Alzheimer's Disease Associated With or Without White Matter Changes After Rivastigmine Patch Therapy - Multi-center, Prospective, Open-label Clinical Trial
Sponsor: Dong-A University
This NA trial investigates Alzheimer's Disease and is currently completed. Dong-A University leads this study, which shows 7 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
▶ Show 2 earlier versions
-
Mar 2018 — Jun 2018 [monthly]
Completed NA
Status: Unknown Status → Completed
-
Jan 2017 — Mar 2018 [monthly]
Unknown Status NA
First recorded
Jun 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Dong-A University
- Novartis Korea Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .